Which drug brands of oral factor b inhibitors are recognized for having fewer side effects? in united states

Short answer:
*In the United States there are no FDA‑approved oral drugs that specifically inhibit complement Factor B. The only oral agent that interferes with the same part of the complement system (the alternative‑pathway amplification loop) is avacopan—a C5a‑receptor antagonist that is still in phase 3 studies for ANCA‑associated vasculitis. Because it is oral and does not block the terminal complement complex, it has a side‑effect profile that is generally considered “lighter” than the IV complement inhibitors (eculizumab, ravulizumab, etc.), although it can still raise blood